WL Gore & Associates, a manufacturing company specializing in products derived from fluoropolymers, has made Hybrid Vascular Graft available in the US.
The device expands treatment options and improves blood flow for dialysis access patients with end-stage renal disease (ESRD.
The GORE Hybrid Vascular Graft is indicated for use as a vascular prosthesis for dialysis access or bypass for other peripheral vascular diseases.
The expanded polytetrafluoroethylene (ePTFE) vascular prosthesis has a section reinforced with nitinol.
The nitinol reinforced section is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations.
It is the only combination graft that incorporates Carmeda BioActive Surface (CBAS Surface) end-point immobilization of heparin to the luminal surface, resulting in a proven thromboresistant surface.
The device is designed to address the most common causes of graft failure; intimal hyperplasia, thrombosis and seroma.
WL Gore said the device simplifies access to vessels with a new over the wire deployment method through a smaller than usual incision in the skin that reduces vessel injury and dissection.